Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

The CDE of China's NMPA has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second BTD.

While the UK continues its close 25-year partnership with Gavi, the US is halting funding to the organisation. In a move that ...

The US FDA has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use ...

Novartis has completed its previously announced acquisition of Regulus Therapeutics for $1.7bn, strengthening its renal ...

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all ...

Scientific experts are concerned about what role vaccines will play in US public health strategy under the Trump ...

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

Revolution Medicines has partnered Royalty Pharma for $2bn to support development and commercialisation of its RAS(ON) ...

The evolving landscape of vaccine oversight makes it key to maintain public trust and keep scientific integrity at the ...

The US FDA has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid.

Medera and Novoheart have collaborated with University of California San Diego School of Medicine and Mayo Clinic mini-heart ...